HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development
Jianming Hu1, Kuancheng Liu2, Jun Luo2
1Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA, 17033, USA. juh13@psu.edu.
Insights
Hepatitis B (HBV) and C (HCV) liver diseases, including cancer, are growing concerns for HIV patients. Effective antiviral therapies offer hope but require careful selection for coinfected individuals.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis B (HBV), C (HCV), and human immunodeficiency virus (HIV) share transmission routes, leading to common coinfections.
- HIV-induced immunodeficiency increases HBV and HCV persistence, while anti-HIV drugs can cause liver damage.
Purpose of the Study:
- To review the impact of HIV on HBV/HCV-related liver diseases, including hepatocellular carcinoma (HCC).
- To discuss the implications of current antiviral therapies for coinfected patients.
Main Methods:
- Literature review of studies on HIV/HBV, HIV/HCV, and HIV/HBV/HCV coinfections.
- Analysis of disease progression, hepatocarcinogenesis, and treatment outcomes.
Main Results:
- HIV coinfection elevates the risk of HBV/HCV persistence and progression to cirrhosis and HCC.
- Hepatotoxicity from anti-HIV therapy can exacerbate liver disease in coinfected individuals.
- Successful HCV cure and effective HIV/HBV suppression are achievable with judicious therapy selection.
Conclusions:
- Managing liver disease in coinfected patients requires careful consideration of shared transmission and treatment interactions.
- Advances in antiviral therapy provide hope but necessitate strategic treatment choices for optimal patient outcomes.
Abstract:
Liver diseases that are caused by the hepatitis B virus (HBV) and hepatitis C virus (HCV), including cirrhosis and hepatocellular carcinoma (HCC), have become increasingly important in patients infected with the human immunodeficiency virus (HIV) as their life expectancy is getting longer with successful anti-HIV therapy. Due to their shared transmission routes, dual infection by HIV and HBV or HIV and HCV, and triple infection by all three viruses are fairly common and affect millions of people worldwide. Whereas the immunodeficiency caused by HIV enhances the likelihood of HBV and HCV persistence, hepatotoxicity associated with anti-HIV therapy can worsen the liver diseases associated with HBV or HCV persistence. Evidence suggests HIV infection increases the risk of HBV- or HCV-associated HCC risk although the precise mechanisms of enhanced hepatocarcinogenesis remain to be fully elucidated. Recent success in curing HCV infection, and the availability of therapeutic options effective in long-term suppression of both HIV and HBV replication, bring hope, fortunately, to those who are coinfected but also highlight the need for judicious selection of antiviral therapies.
Related Concept Videos
Liver Histology
Hepatocytes perform a variety of essential functions. They secrete...
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Gross Anatomy of the Liver
Located under the diaphragm, the liver is almost entirely ensconced within the rib cage, providing it with substantial protection. Except for the superior most bare area, the liver's surface is...
Sustainable Development
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...


